Introduction
============

In the two decades since the amyloid hypothesis was first proposed \[[@B1]\], a great deal of evidence has accrued in support of this mechanism in the pathogenesis of Alzheimer\'s disease (AD), mostly from preclinical studies of transgenic mice, autosomal dominant presenilin cases, and *in vitro*data supporting the neurotoxic effects of amyloid-beta (Aβ). The theoretical promise of this model, however, has yet to be realized in the world of AD therapeutics. Robust treatments still seem elusive, even with an identified therapeutic target. Others have addressed the question of *why*this may be the case \[[@B2],[@B3]\], and this review builds on that literature.

The process of drug development, from preclinical investigation through phase III study, is shown in Figure [1](#F1){ref-type="fig"}. Considering each phase separately helps to identify confounders that might be driving a type II error, if such an error exists in reference to new drug development for AD.

![**The process of drug development from preclinical investigation through phase III study, with potential confounders**. MMSE, Mini-Mental State Examination.](alzrt73-1){#F1}

Zahs and Ashe \[[@B2]\] reviewed mouse models of AD and made several observations in regard to translational research. These authors identified more than 300 reports of effective AD interventions based on these models. They noted, however, that none of the models is actually a complete replication of AD. In fact, what the models do simulate is a presymptomatic phase of AD, which might correspond to a time many years before a patient would present to a memory clinic or a subject would present to a clinical trial.

Becker and Greig \[[@B3]\] identified approximately 100 candidate drugs for AD with more than 40 different mechanisms of action, and 20 of those 100 drugs showed early promise through phase II studies. Table 1 of the authors\' report shows a representative sample of 16 drugs trialed within the last decade, and most of them failed because of lack of efficacy in phase III study. Trials of these drugs are reviewed in more detail below.

Immunotherapy: AN1792
=====================

This was the first trial in humans of an active immunotherapy approach, in which Aβ42 was introduced as an antigen to stimulate antibody production against the entire Aβ molecule, thus promoting clearance of amyloid. AN1792 is unique among the drugs discussed here because it ceased development because of *safety*concerns related to the occurrence of meningoencephalitis, a T cell-mediated inflammatory process that occurred in 6% of treated patients \[[@B4]\]. Responders were noted to have functional benefit after one to three doses, and antibodies were persistent for 5 years or more \[[@B5]\]. Overall, clinical benefits of the vaccine were modest, although survivor analysis favored treatment \[[@B5]\]. However, a *post hoc*study of subjects who were enrolled in the AN1792 study and who came to autopsy revealed that immunization with Aβ42 (AN1792) resulted in clearance of amyloid plaques in patients with AD but this clearance did not prevent progressive neurodegeneration \[[@B6]\]. Limited data from the trial suggested that immunotherapeutic interventions should be administered early in the course of the disease. Second-generation immunotherapy trials are now in progress.

Cholinergic drugs: phenserine and AZD3480
=========================================

Phenserine, a derivative of physostigmine, is a selective, noncompetitive acetylcholinesterase inhibitor that has additional effects on Aβ levels \[[@B7]\]. Phenserine interacts with the 5\'- untranslated region of the APP (amyloid beta (A4) precursor protein) gene and reduces translation of APP mRNA into protein. Both the (-)- and the (+)-enantiomer of phenserine are equipotent in dose-dependent and time-dependent negative regulation of APP mRNA translation, but (+)-phenserine (posiphen) is inactive as an acetylcholinesterase inhibitor and therefore may be administered at higher doses \[[@B8]\].

In a phase IIb study in 20 patients with mild AD, phenserine 30 mg/day reduced cerebrospinal fluid (CSF) levels of Aβ as well as formation of amyloid plaques (as measured by retention of cortical Pittsburgh compound B-positron emission tomography, or PIB-PET) \[[@B9]\]. In a 6-month phase III trial in 384 patients with mild to moderate AD (Mini-Mental State Examination (MMSE) score of at least 10 and not more than 26), participants were randomly assigned to receive phenserine 10 or 15 mg twice daily or placebo. At the completion of the trial, no significant differences were found between the phenserine and placebo groups on the Alzheimer\'s Disease Assessment Scale-cognitive subscale (ADAS-cog) or the Clinician\'s Interview-Based Impression of Change (CIBIC), the primary outcome measures. Two concurrent clinical trials were halted, and the data from these were merged for analysis, which also failed to demonstrate benefit of phenserine compared with placebo \[[@B10]\].

AZD3480 is an α4β2-selective nicotinic acetylcholine receptor (nAChR) agonist \[[@B11]\]. nAChRs in the central nervous system (CNS) are believed to be the primary cholinergic receptors lost in AD, and agonists at these receptors were hypothesized to be viable symptomatic treatments. In the Sirocco Trial, subjects with mild to moderate AD (*n*= 659) were randomly assigned to receive one of three doses of AZD3480, a fixed dose of donepezil, or placebo for 12 weeks \[[@B12]\]. Although AZD3480 was comparable to placebo in terms of its overall safety and tolerability profile and was associated with fewer gastrointestinal-related adverse effects than donepezil, neither AZD3480 nor donepezil was significantly positive on the primary outcome measure (ADAS-cog) \[[@B12]\]. This is one of many trials in which improvement in the placebo group over time affected outcome. In addition, there was some concern that the study was too brief to detect a positive outcome, even for a symptomatic treatment. The minimum duration of a treatment trial is usually on the order of 24 weeks.

Neuroprotection: *Ginkgo biloba*
================================

*G. biloba*is an herbal supplement that is widely believed to have efficacy in the prevention and treatment of aging-associated cognitive decline, including AD. Evidence suggests that this drug facilitates the clearance of Aβ through regulation of the receptor for advanced glycation end-products and LRP-1 (low density lipoprotein receptor-related protein 1) during brain ischemia \[[@B13]\]. Studies of the efficacy of this drug have had mixed results. An important and influential study was the National Institutes of Health-sponsored clinical trial at five academic medical centers between 2000 and 2008; in that study, an extract of *G. biloba*120 mg twice daily or placebo was administered to 3,069 elderly community-dwelling volunteers (2,587 with normal cognition and 482 with amnestic mild cognitive impairment, or MCI) \[[@B14]\]. Participants were evaluated every 6 months for the primary outcome measures of incident dementia and AD (determined by expert panel consensus). The results indicated no significant effect of *G. biloba*on the progression to AD (hazard ratio (HR) = 1.16, 95% confidence interval (CI) 0.97 to 1.39) or all-cause dementia (HR = 1.12, 95% CI 0.94 to 1.33). A subset analysis in participants with amnestic MCI at baseline had similar results (HR = 1.13, 95% CI 0.85 to 1.50). Overall, a greater number of subjects treated with *G. biloba*developed dementia (*n*= 277; 3.3 per 100 person-years) in comparison with placebo (*n*= 246; 2.9 per 100 person-years), but the difference was not statistically significant. The findings of this study suggested no role for *G. biloba*in the prevention of AD or incident cognitive decline \[[@B14],[@B15]\]. Meta-analyses of the studies of *G. biloba*in the treatment and prevention of dementia and cognitive decline show variable effects with an inconsistent signal \[[@B16],[@B17]\]. The data in aggregate are contrary to the widely held view that Ginkgo prevents memory decline and, in fact, are contrary to earlier findings. In the larger community of outpatients, it is possible that Ginkgo self-administration is actually a marker for a healthy lifestyle, with high compliance by virtue of voluntary administration.

Glutamatergic drugs: neramexane and SGS742
==========================================

Neramexane is an *N*-methyl *D*-aspartate (NMDA) receptor antagonist similar to memantine. These drugs are thought to reduce excitoxicity associated with excessive glutamatergic stimulation. In phase II trials, neramexane demonstrated reasonable safety and tolerability \[[@B18]\]. Presumably because of poor efficacy, the drug was not entered into phase III trials for AD; instead, the drug is under investigation for the treatment of tinnitus and pain. Given the mechanism of the drug, it would not be expected to influence disease progression in AD.

SGS742 is an orally active phosphoamino acid derivative that acts as a selective gamma-aminobutyric acid type B (GABA~B~)-receptor antagonist \[[@B19]\]. This drug was considered as a potential treatment for AD because activation of GABA~B~receptors had been found to inhibit memory/learning in animal models \[[@B19]\]. It was hypothesized that GABA~B~antagonists might reverse this effect by reducing glutamatergic excitotoxicity via indirect effects on NMDA receptors. Preclinical studies in rats, mice, and rhesus monkeys were positive. In the first phase II trial (*n*= 110) in MCI, SGS742 was well tolerated at a dose of 600 mg three times daily for 8 weeks \[[@B19]\]. Positive effects on attention, visual information processing, and working memory were demonstrated. In a phase IIb monotherapy trial (*n*= 280) in mild to moderate AD, SGS742 failed to meet the efficacy endpoints.

Hormonal therapies: estrogen and leuprolide
===========================================

Hormone replacement therapy (HRT) has been proposed as a target for treatment and prevention in AD because of dampening effects on Aβ demonstrated in preclinical studies \[[@B20],[@B21]\]. A meta-analysis of 10 studies linked estrogen with a higher risk of dementia, a lower risk of dementia, and no association with dementia or AD \[[@B22]\]. A second meta-analysis noted a slight but inconsistently positive effect of estrogen on cognitive health \[[@B23]\]. A third meta-analysis concluded that, given the problems with study conduct and methodology plaguing studies of estrogen and cognition, the association between HRT and dementia risk was still unknown \[[@B24]\].

Results of the Women\'s Health Initiative Memory Study (WHIMS) indicate that HRT was *not*associated with a lower risk of dementia and in fact may be associated with an *increased*risk of dementia \[[@B25]\]. Subjects administered the combined HRT regimen of estrogen and progestin were twice as likely to develop dementia in comparison with those not treated with HRT. In a later WHIMS study, which looked at the use of estrogen monotherapy for women who previously had a hysterectomy, subjects on HRT had a 49% higher incidence of probable dementia during follow-up \[[@B26]\]. Both estrogen trials were terminated - estrogen and progestin in July 2002 and estrogen alone in February 2004 - because of adverse cardiovascular and stroke events and concern over increased breast cancer risk.

Trials of HRT in subjects with established AD have also been mostly negative. If HRT is to be pursued as prophylaxis or treatment of AD, the investigation will likely focus on several unresolved issues, including the timing and duration of exposure required, and possible differences with the use of bioidentical or synthetic hormones.

As age is the leading risk factor for AD, the question of whether the cause of AD is also age-related naturally arises. It is well established that estrogen and testosterone levels decline with age and that levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) rise because of reduced negative feedback to the HPA axis \[[@B27]\]. These gonadotropins stimulate not only gonadal steroid synthesis but also cell proliferation in the gonads, where AβPP and presenillins are highly expressed. LH receptors are present on neurons and are particularly abundant in the hippocampus. A preclinical study suggested that lowering LH levels might be beneficial in AD \[[@B28]\]. Increased LH levels have been found in brain in patients with AD \[[@B29],[@B30]\]. Treatment of C57/Bl6 wild-type mice with leuprolide decreases Aβ levels. Leuprolide is known to lower LH levels in humans and is marketed for the treatment of prostate cancer. In phase III trials, however, leuprolide failed because of lack of efficacy.

Serotonin 5HT~1A~receptor antagonists: xaliproden
=================================================

Xaliproden was considered for the treatment of AD because of its nerve growth factor-like effects and its antagonism of the serotonin 1A (5-HT~1A~) receptor \[[@B31]\]. Consideration of 5-HT~1A~antagonists for AD was based on preclinical data indicating that they facilitated glutamatergic and cholinergic neurotransmission \[[@B31]\] and that inhibition of the 5-HT~1A~receptor resulted in the enhancement of cognitive abilities \[[@B31]\]. Two large phase III, 18-month clinical trials of xaliproden monotherapy (*n*= 1,306) and adjunctive therapy (*n*= 1,455) in patients with mild to moderate AD (MMSE score of 16 to 26) were completed in 2007 \[[@B32]\]. Lack of efficacy in both trials resulted in the cancellation of the xaliproden development program for AD in September 2007.

Gamma secretase modulator: tarenflurbil
=======================================

Tarenflurbil, the [R]{.smallcaps}-enantiomer of the nonsteroidal anti-inflammatory drug flurbiprofen, was the first gammasecretase modulator to reach the final stage of clinical development. Results of a phase II trial in 210 patients studied for 18 months did not meet the primary end-point, but a *post hoc*analysis of subjects with mild AD (MMSE score of 20 to 26) found beneficial effects of tarenflurbil at a dose of 800 mg twice daily in terms of measures of daily activities and global function \[[@B33]\].

The 18-month phase III trial (*n*= 1,600), conducted at 133 sites in the US, examined the effect of tarenflurbil 800 mg twice daily in patients with mild AD (mean MMSE score of 23, range of 20 to 26), 81% of whom were receiving a stable dose of an acetylcholinesterase inhibitor, memantine, or a combination of these drugs \[[@B34]\]. The primary outcome measures were the ADAS-cog and ADAS activities of daily living (ADAS-ADL) scale, assessed every 3 months. There was no significant difference between the tarenflurbil and placebo groups; at the end of the study, both groups had declined by mean values of 7 points on the ADAS-cog and 10 points on the ADAS-ADL. With this magnitude of decline over 18 months, an efficacy signal should have been detectable. It is possible, as some have speculated, that tarenflurbil given orally did not adequately penetrate the CNS. It is also possible that gamma secretase modulation is best initiated before any plaque deposition has occurred (for example, in patients at risk of AD) and therefore would exert minimal effects with significant amyloid burden as is common in symptomatic AD.

Statin drugs
============

Elevated midlife cholesterol levels are associated with an increased risk of AD \[[@B35]\], and chronic use of hydroxy-methylglutaryl coenzyme [A]{.smallcaps}-reductase inhibitors (statins) has been reported to reduce the risk of developing AD by up to 75% \[[@B36]\]. In addition, robust scientific data indicate that hypercholesterolemia promotes Aβ production and deposition in a variety of animal models of AD and that cholesterol reduction strategies reduce Aβ deposition \[[@B37]\]. Another study indicates that statins inhibit Aβ formation *in vitro*\[[@B38]\].

Although a phase II study of atorvastatin 80 mg/day monotherapy in 63 patients with mild to moderate AD found that the treated group had no deterioration in scores on cognitive or functional assessment scales after 12 months of treatment \[[@B35]\], a larger phase III study (*n*= 600) in patients also receiving donepezil was completed in 2007 and found no benefit to adjunctive use of atorvastatin \[[@B39]\]. A phase III trial (*n*= 400) of simvastatin monotherapy was also completed in 2007, and the results were reported to be negative as well.

Despite these negative findings, the epidemiologic data suggesting a protective effect (as opposed to a treatment effect) of statins in AD \[[@B40]\] are sufficiently encouraging that simvastatin 80 mg/day is now in a phase II trial prevention study. This study plans to enroll 100 adults (35 to 69 years old) who have a parent with AD but who do not themselves exhibit any cognitive deficits. The primary outcome measures are CSF Aβ, inflammatory markers, and cholesterol as well as cognitive performance over time (Evaluating Simvastatin\'s Potential Role In Therapy (ESPRIT) \[[@B32]\].

Insulin sensitizer: rosiglitazone
=================================

Insulin signaling is known to have a role in memory function and may also influence the regulation of APP and Aβ \[[@B41]\]. In addition, insulin-degrading enzyme is one of the enzymes active in clearance of Aβ \[[@B42]\]. For these reasons, insulin abnormalities are of interest as causes of or contributors to cognitive impairment, and insulin resistance has been proposed as a potential target for AD prevention. Rosiglitazone acts as an insulin sensitizer, binding to receptors in fat cells that render the cells more responsive to insulin \[[@B43]\]. In the phase II trial (*n*= 511), no difference between the rosiglitazone and placebo groups was found in the population as a whole, but an interaction between *ApoE ε4*genotype and outcome was identified in those on the highest dose of drug \[[@B44]\]. Specifically, non-*ε4*carriers were found to improve on rosiglitazone 8 mg. No serious safety concerns were noted. In the phase III trials, patients were stratified by *ApoE ε4*status. Regardless of whether rosiglitazone was used as monotherapy or adjunctive therapy, efficacy for mild to moderate AD was not demonstrated by either the ADAS-Cog or the CIBIC-plus. In meta-analyses unrelated to AD trials, cardio-vascular morbidity with rosiglitazone was identified \[[@B45]\]. This safety concern will likely limit the scope of investigation for rosiglitazone for AD.

Glycosaminoglycan mimetic: tramiprosate
=======================================

Structurally, tramiprosate is a glycosaminoglycan (GAG) mimetic designed to interfere with the actions of Aβ early in the cascade of amyloidogenesis \[[@B46]\]. Tramiprosate is a modification of the amino acid taurine. It binds preferentially to soluble Aβ peptide and maintains Aβ in a nonfibrillar form, thereby inhibiting amyloid formation and deposition. Tramiprosate also interferes with β-sheet formation of amyloid.

In the phase II clinical trial, subjects randomly assigned to tramiprosate demonstrated sustained safety and tolerability as well as a reduction in CSF Aβ42 levels \[[@B47]\]. Additionally, the treated subjects remained near baseline as measured by ADAS-Cog after 20 months of treatment.

The phase III trial, which was conducted in 67 centers throughout North America, randomly assigned 1,052 patients with mild to moderate AD to tramiprosate 100 and 150 mg twice daily or placebo \[[@B48]\]. Continued use of approved AD medications was allowed. The primary endpoints were the ADAS-Cog score, the Clinical Dementia Rating Scale-Sum of Boxes score, and change in hippocampal volume on magnetic resonance imaging. Tramiprosate was not significantly more effective than placebo on any of these outcome measures. In November 2007, the sponsor announced its intention to discontinue development of tramiprosate as a pharmaceutical and halted the European phase III trial. Again, a confounder of the phase III trial was an unusually strong placebo response \[[@B48]\]. In addition, there is some evidence that tramiprosate acts to promote the aggregation of tau protein \[[@B46]\]. Since 2008, tramiprosate has been marketed as the over-the-counter nutraceutical Vivimind.

Chelating agents: clioquinol (PBT1)
===================================

Proponents of chelation therapy have focused on identifying and extracting metallic ions co-localized to plaques. Clioquinol, an anti-malarial drug no longer used (because of toxicity to peripheral and optic nerves), has been shown to inhibit zinc and copper ions from binding to Aβ, thus promoting the solubilization and clearance of Aβ. A pilot phase II clinical trial was conducted in 36 subjects with moderate AD. The effect of treatment was significant in the more severely affected group (baseline ADAS-Cog score of at least 25) but the effect was attributed to substantial worsening of scores in those taking placebo in comparison with minimal deterioration for the clioquinol group. Plasma Aβ42 levels declined in the clioquinol group and increased in the placebo group. Plasma zinc levels rose in the clioquinol-treated group. The drug was well tolerated. These data suggest that clioquinol improved cognition and lowered plasma levels of Aβ42 in some patients. However, a phase III study was never undertaken and clioquinol is no longer in development for the treatment of AD \[[@B49]\].

Conclusions
===========

In general, review of failed drug trials in AD can be productive if pitfalls that can be avoided in future trials are identified. Several general findings are worth noting. Except for the early vaccine trials and rosiglitazone, the major obstacle facing drug development over the last decade appears to be lack of demonstrated efficacy rather than safety. The logical possibilities to explain inefficacy are that the drugs developed thus far are simply ineffective in humans, that the amyloid hypothesis is not the right model, that the drugs are administered incorrectly (wrong dose, route, or disease stage), or that the drugs are working but the clinical trial complex is unable to detect the signal.

The drugs are not effective in humans
-------------------------------------

The possibility does exist that, at least for some of the drugs trialed, preclinical data are misleading. *In vitro*models may be too simplistic, lacking the complex interactions of pharmacokinetics and pharmacodynamics with physiology. Transgenic mouse models do not provide a true representation of AD, as noted earlier. Many of the models lack pathological characteristics such as tangles, or plaque morphology and dissolution characteristics are different from those of human AD plaque. Thus, some drugs shown to work *in vitro*and *in vivo*may never be efficacious in humans. Alternatively, since animal studies are not a true reflection of the disease process in AD in humans, the disease in humans may be too advanced or too widespread at the symptomatic phase to be amenable to meaningful clinical effect.

The amyloid hypothesis is not the right model
---------------------------------------------

It would be difficult at this point to argue that the amyloid hypothesis does not describe at least some component of the pathogenetic pathway of AD. Amyloid immunotherapies have become a common approach to targeting the disease, but the results to date have not been consistently positive nor does targeting amyloid pathology change the outcome \[[@B6]\]. This does not rule out the possibility, however, that tau or other pathologies (or both) should also be targeted.

The drugs are administered incorrectly
--------------------------------------

Clinical trialists working in phase II and III studies have to trust that adequate time and attention have been paid in earlier phases of drug development to the identification of the appropriate drug dose. For the most part, this has not proven problematic. More important to drug success is the observation, already stated, that the AD mouse model more closely parallels preclinical AD, so for drugs developed along this pathway, the focus of investigation should be on asymptomatic at-risk individuals or those with very early MCI. For the latter group, it would be important to avoid using the MMSE as a screening tool for subject inclusion/exclusion. In part because of ceiling effects and in part because of practice effects with the MMSE, potential subjects are often excluded by this measure even though it is clear that they are impaired from baseline. A more sensitive screening instrument such as the Montreal Cognitive Assessment could be used in place of the MMSE \[[@B50]\].

The drugs work but clinical trials are not detecting efficacy
-------------------------------------------------------------

Of the available explanations for failed trials, this appears to be the most likely candidate. Even a cursory look at clinical trial conduct reveals a number of potential problems, many of which are amenable to correction. One of the most significant problems from the standpoint of the clinical trialist is the heavy reliance on rating scales as outcome measures \[[@B3]\]. Regardless of the quality of rater training, any degree of subjectivity in assessment will introduce variance across sites and over time. Even for ostensibly \'objective\' instruments such as the ADAS-Cog, which is the most widely used measure of cognitive change in AD trials, variations in forms, administration procedures, and scoring rules exist \[[@B51]\]. More widespread use of human amyloid imaging is a critical next step in the improvement of outcome measures for AD trials.

The fact that so many of the AD drug trials failed in moving from phase II to phase III provides a clue as to other problems plaguing drugs under investigation. One factor that changes between these two phases is that the study population becomes more heterogeneous, and with this change comes the possibility that as-yet-unidentified confounding medical problems and medications will be introduced. As trials get larger, are \'less eligible\' subjects enrolled? In addition, the group of trialists and research centers expands in moving to phase III, reaching out beyond the inner circle of investigators and coordinators. At least in some trials, the added personnel are relatively lacking in experience with the drug, not having been involved in phase I or II activities.

Another issue relates to the short duration of many clinical trials. Long trials are very difficult to conduct in elderly patients with a progressive disease like AD, particularly since it also so profoundly affects caregivers, who usually serve as study partners. In addition, new drug development is big business, and the push to obtain data in support of a new drug application is a fact of life for the pharmaceutical industry. Those who conduct clinical trials are sometimes left to wonder whether an extension might turn a negative trial into a positive one.

Unexpected and large improvements in placebo populations have plagued several of the trials for AD. This improvement is actually understandable from the point of view of the clinical trialist. Individuals enrolled in AD trials are seen on a regular basis by caring individuals who have a good understanding of how to talk to patients with dementia and how to deal with problematic behaviors. Whether specific non-trial-related interventions are undertaken or not, positive interactions at these visits are bound to have beneficial effects. This is a difficult area to remedy without offense, but some thought should be given to ways in which the patient contacts could be \'sterilized\' to help neutralize this effect. In addition, it could be expected that, given enough time, the placebo group would naturally decline. Perhaps a rule of thumb could be stated as follows: if your placebo group does not decline, your trial is too short.
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